Niclosamide in Cancer Immunotherapy: Breaking Through Tumor Immune Evasion

Cancer researchers have spent decades staring at the same problem: the immune system can find cancer cells, but tumors keep slipping away. Why? A lot of it comes down to the tumor microenvironment—the neighborhood around a tumor where cancer cells essentially run a protection racket.

Research from Carnegie Mellon University, published in Frontiers in Immunology in March 2026, suggests an old drug might help. Niclosamide has been around since the 1960s as a treatment for tapeworm infections. Now researchers are asking whether it could work against cancer too.

What’s Going Wrong in the Tumor Microenvironment

The area around a tumor isn’t just empty space. It’s full of activity, and cancer cells have learned to exploit it.

PD-L1 is the problem on one end. Tumor cells display PD-L1 proteins on their surfaces. When T cells bump into these proteins, they essentially shut down. The T cell was ready to attack, and then—nothing.

Cancer stem cells are the problem on the other. These are a small subset of cells within tumors that can regrow the entire tumor, spread to new locations, and survive treatments that kill the bulk of cancer cells. They’re the reason tumors often come back after treatment.

Here’s the thing researchers found: IFN-γ, a signal immune cells send when they’ve spotted trouble, actually makes both problems worse. It uses one pathway (STAT1) to ramp up PD-L1, while simultaneously using another pathway (STAT3) to increase cancer stem cell populations. IFN-γ is supposed to help fight cancer. Instead, it can play into the tumor’s hands.

The STAT1-STAT3 See-Saw

When researchers blocked STAT1 to lower PD-L1, STAT3 activity went up. When they blocked STAT3, STAT1 activity increased. It’s a see-saw—if you push one side down, the other goes up.

This explains a lot about why single-target cancer drugs often disappoint. Knock down one evasion mechanism, and the tumor just leans harder on another.

What Niclosamide Does

Niclosamide blocks both STAT1 and STAT3 at the same time. In lab experiments with mouse colon cancer cells, treatment led to:

• Less PD-L1 on the cell surfaces (because STAT1 was blocked)
• Fewer cancer stem cell markers (because STAT3 was blocked)
• Lower HIF-1α levels, even in low-oxygen conditions

HIF-1α matters because hypoxic tumors—those running low on oxygen—are especially hard to treat. They resist immunotherapy and tend to grow back. By hitting HIF-1α alongside the STAT pathways, niclosamide addresses a particularly stubborn type of tumor.

What Happens to T Cells

The researchers didn’t just look at cancer cells. They also checked what happened to T cells when niclosamide was added.

In tumor sphere experiments where cancer cells and T cells were grown together, adding niclosamide:

• Cut down the number of exhausted T cells (cells carrying both PD-1 and Tim-3 markers, signs they’ve given up)
• Helped T cells infiltrate into the tumor spheres
• Improved how well T cells killed cancer cells

The effects held up even under low-oxygen conditions, where T cells usually struggle to function.

Why This Drug Might Actually Work in Practice

Niclosamide isn’t a new experimental compound. Doctors have prescribed it for tapeworm infections for over 60 years. That means we know a lot about how it behaves in people—the side effects, how the body processes it, who shouldn’t take it.

It’s also available as a pill, not an injection. For cancer patients, that’s not nothing.

As a generic drug, it’s cheap to make. If it works, it could reach patients who might otherwise lack access to expensive treatments.

What This Means for Treatment

The obvious next step is combining niclosamide with checkpoint inhibitors—drugs like anti-PD-1 that are already used in many cancers. Checkpoint inhibitors block the PD-1/PD-L1 interaction directly, but some patients don’t respond, and others stop responding over time.

Niclosamide might help by lowering PD-L1 levels and reducing cancer stem cell populations before checkpoint inhibitor treatment even starts. It’s not replacing existing treatments—it’s trying to make them work better.

What’s Still Unknown

This research was done in dishes and mice. Human trials haven’t happened yet. We don’t know the right dose for cancer, whether it will combine safely with existing drugs, or which patients might benefit most.

The path from lab results to approved treatment is long and uncertain. But drug repurposing—finding new uses for old drugs—can move faster than starting from scratch. We already know the drug is safe. We just need to figure out if it helps cancer patients.

Looking Ahead

Cancer won’t be solved by hitting one target at a time. The tumor microenvironment is complex, and tumors adapt. Drugs that can address multiple pathways simultaneously might have an edge.

Niclosamide has a long history as a parasite treatment. Whether it becomes part of cancer care depends on what comes next—careful studies, real patient data, and time. The early results are worth paying attention to, but caution is warranted. Good science moves incrementally, even when headlines suggest otherwise.

---

Frequently Asked Questions (FAQ)

What is niclosamide and how does it work against cancer?

Niclosamide is an old antiparasitic drug approved by the FDA in the 1960s for treating tapeworm infections. Researchers discovered it can block STAT1 and STAT3 signaling in cancer cells, which lowers PD-L1 expression and reduces cancer stem cell populations. This dual action may help tumors become more visible to the immune system.

How is niclosamide different from current immunotherapy drugs?

Most available immunotherapies focus on blocking the PD-1/PD-L1 interaction directly. Niclosamide takes a broader approach—it inhibits multiple signaling pathways at once, including STAT1, STAT3, and HIF-1α. This might make it useful alongside existing drugs rather than as a replacement.

Which cancer patients might benefit from niclosamide?

The research focused on solid tumors with low-oxygen regions, including colorectal cancer models. Hypoxic tumors tend to resist immunotherapy, so these might be the first candidates for testing. Clinical trials would need to confirm which patients could benefit.

Is niclosamide safe for cancer patients?

The drug has a long safety record for treating parasites. But cancer treatment would probably require different doses and schedules. Clinical trials are the only way to determine whether it’s safe and effective in this context.

When could niclosamide be available for cancer treatment?

Right now, this research exists only in labs and animal models. Human trials haven’t begun. The timeline from here to approval—if it gets approved—could take years and depends on trial results.

Can niclosamide be combined with other cancer therapies?

The study suggests niclosamide might work well with checkpoint inhibitors. By lowering PD-L1 and cancer stem cell populations first, it could make subsequent immunotherapy more effective. This combination hypothesis needs testing in clinical trials.

What are cancer stem cells?

Cancer stem cells are a small group of cells within tumors that can self-renew and produce all the other cell types in a tumor. They’re why tumors often grow back after treatment. Targeting these cells might improve long-term outcomes.

What is the tumor microenvironment?

The tumor microenvironment is the ecosystem around a tumor—other cells, blood vessels, signaling molecules, and physical conditions like oxygen levels. Tumors shape this environment to their advantage, making it harder for the immune system to work.